dc.contributor.author | Bay, Sema Buyukkapu | |
dc.contributor.author | Zulfikar, Bulent | |
dc.contributor.author | Kebudi, Rejin | |
dc.date.accessioned | 2021-03-03T15:14:35Z | |
dc.date.available | 2021-03-03T15:14:35Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Bay S. B. , Kebudi R., Zulfikar B., "Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency", MELANOMA RESEARCH, cilt.29, sa.1, ss.99-101, 2019 | |
dc.identifier.issn | 0960-8931 | |
dc.identifier.other | av_3e00066a-ab18-4031-b79d-5184ce9712e8 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/45538 | |
dc.identifier.uri | https://doi.org/10.1097/cmr.0000000000000537 | |
dc.description.abstract | Malignant melanoma is very rare in childhood. The approach to diagnosis and treatment in children has been adopted from adult guidelines. Vemurafenib is indicated in adults with BRAF V600 mutation-positive stage IIIc/IV melanoma and causes cutaneous adverse events. We report on a 3-year-old child with recurrent, metastatic (bone) BRAF mutation-positive melanoma. He also had severe factor X deficiency. Four days after vemurafenib treatment, bilateral palpebral edema and violet-colored hyperpigmentation were observed. There was no objective response to vemurafenib; however, bone pain regressed slightly. Our patient is the youngest patient who received vemurafenib for BRAF V600 mutation-positive metastatic melanoma in the literature. | |
dc.language.iso | eng | |
dc.subject | Dermatoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Tıbbi Ekoloji ve Hidroklimatoloji | |
dc.subject | Reviews and References (medical) | |
dc.subject | Research and Theory | |
dc.subject | Oncology | |
dc.subject | Dermatology | |
dc.subject | Health Sciences | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | TIP, ARAŞTIRMA VE DENEYSEL | |
dc.subject | DERMATOLOJİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency | |
dc.type | Makale | |
dc.relation.journal | MELANOMA RESEARCH | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 29 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 99 | |
dc.identifier.endpage | 101 | |
dc.contributor.firstauthorID | 262061 | |